Esophageal abscess complicating endoscopic treatment of refractory gastroesophageal reflux disease by Enteryx injection: a first case report.
Enteryx (Boston Scientific) is an injectable solution containing 8% ethylene vinyl alcohol copolymer dissolved in dimethyl sulfoxide that has been approved for the treatment of gastroesophageal reflux disease (GERD). The technique consists of injecting Enteryx into the lower esophageal sphincter where it solidifies into a sponge-like permanent implant and prevents or reduces gastric acid reflux into the esophagus. The procedure appears to be generally safe, even if minor or moderate adverse events have been observed. We present the case of a 52-yr-old female treated by Enteryx injection for GERD who developed subsequently an esophageal parietal abscess.
Departments of Internal Medicine and Nephrology, Clinique et Maternité Sainte Elisabeth, Place Godin 15, 5000 Namur, Belgium.
Michel
M
Tintillier
André
A
Chaput
Lotti
L
Kirch
Jean-Paul
JP
Martinet
Jean-Michel
JM
Pochet
Charles
C
Cuvelier
D000038:Abscess / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D000900:Anti-Bacterial Agents; D018450:Disease Progression; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004935:Esophageal Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D004943:Esophagogastric Junction / Q000187:drug effects* / Q000473:pathology; D004945:Esophagoscopy; D017809:Fatal Outcome; D005260:Female; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D015552:Injections, Intralesional; D008875:Middle Aged; D011145:Polyvinyls / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index
D000900:Anti-Bacterial Agents; D011145:Polyvinyls; C020320:ethylene-vinyl alcohol copolymer